Alpine Immune Sciences Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Alpine Immune Sciences's estimated annual revenue is currently $6.8M per year.
- Alpine Immune Sciences received $48.0M in venture funding in June 2016.
- Alpine Immune Sciences's estimated revenue per employee is $117,586
- Alpine Immune Sciences's total funding is $52.6M.
- Alpine Immune Sciences has 58 Employees.
- Alpine Immune Sciences grew their employee count by 18% last year.
- Alpine Immune Sciences currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Alpine Immune Sciences?
Founded in 2015 by a team responsible for the FDA's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, Alpine Immune Sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. Traded on NASDAQ under ticker ALPN.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Alpine Immune Sciences News
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on ...
We can see that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) does use debt in its business. But should shareholders be worried about its ...
On August 13, 2019, Alpine Immune Sciences, Inc. issued a press release reporting its financial results for the second quarter of 2019. A copy ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
Alpine Immune Sciences Funding
Alpine Immune Sciences Executive Hires
|2016-06-14||Mitchell H. Gold||Executive Chairman/acting Chief Executive Officer||Article|
|2018-08-07||Mark Litto||President & COO||Article|
Alpine Immune Sciences Acquisitions
|2017-07-27||Nivalis Therapeutics, Inc||Complete - Cash in deal||Article|